Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP01A Monotherapy in HIV-Infected Patients
NCT00299897Phase 2
Key facts
- Status
- Unknown
- Start
- Mar 2006
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- procaine
- Conditions
- human immunodeficiency virus infection (HIV)
01
Overview
Phase 2, randomised, double-blind trial of procaine in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Samaritan Pharmaceuticals, Inc. Primary endpoint: Within treatment group reduction in viral load (log10) at Day 29. Status: unknown.
02
Design
4 arms- Study design
- RandomizedDouble-blind
SP01A 200 mg QID
SP01A 200 mg administered four times daily
SP01A 200 mg BID
SP01A 200 mg administered twice daily
SP01A 400 mg BID
SP01A 400 mg administered twice daily
Placebo BID
Placebo administered twice daily
03
Endpoints
Primary
Within treatment group reduction in viral load (log10)
Secondary
Reduction in viral load compared across SP01A active arms
Beyond the preview
Go deeper on NCT00299897.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00299897.